Study #2025-0045
A phase 3 randomized double-blind multicenter study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Sonrotoclax, Zanubrutinib, Placebo
Description
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma, B Cell Lymphoma
Study phase:
Phase III
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.